Actions

Newsfeed Popular Local Discover Follows Blocks Bookmarks Filters Settings PowerUps Help Updates

stocktitan.net / Share Newsitem

View, share or embed this newsitem using the details below.

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma announced the dosing of the first patient in China in a Phase 1b clinical study of the combination of ICP-189 and furmonertinib for NSCLC. The collaboration with ArriVent aims to accelerate the clinical trial, targeting EGFR mutations...

https://newsreadery.com/go/c02f93731829a087e8c9fb68a09b86fd

Save

Back

Read Full Article